Consequently, we focus in this research on development of this hybrid scaffold (Figure 2) to selectively inhibit EGFR/HER2 tyrosine kinases as well as to assess the antiproliferative activity of this new series against prostate carcinoma cell lines. Here, EGFR is linked to prostate carcinoma.